The best hair loss treatment for men depends on the underlying cause, severity, and individual health profile — but for most men, evidence-based options are available. Male pattern baldness (androgenetic alopecia) is by far the most common cause, affecting millions of men in the UK. Two MHRA-licensed medicines — finasteride and topical minoxidil — have the strongest clinical evidence and form the cornerstone of treatment. This article explains the causes of hair loss in men, reviews the treatments supported by clinical evidence, outlines how to access them safely in the UK, and helps you make an informed decision in consultation with a healthcare professional.

Common Causes of Hair Loss in Men

Androgenetic alopecia, driven by genetic sensitivity to DHT, is the most common cause of hair loss in men; other causes include alopecia areata, telogen effluvium, and medication side effects, all of which require different treatment approaches.

Experiencing these side effects? Our pharmacists can help you navigate them →

Hair loss in men is extremely common and, in the majority of cases, has a well-understood medical explanation. The most prevalent cause is androgenetic alopecia, commonly known as male pattern baldness. This condition is driven by a genetic sensitivity to dihydrotestosterone (DHT), a hormone derived from testosterone, which causes hair follicles to miniaturise progressively over time. It typically presents as a receding hairline, thinning at the crown, or both, and can begin as early as the late teens or early twenties.

Beyond androgenetic alopecia, several other conditions can contribute to hair loss in men:

• Alopecia areata – an autoimmune condition causing patchy hair loss, which can affect the scalp, beard, or body hair

• Telogen effluvium – a temporary, diffuse shedding often triggered by physical or emotional stress, illness, nutritional deficiencies, or significant weight loss

• Tinea capitis – a fungal scalp infection that predominantly affects children; adult men are less commonly affected, though cases do occur

• Traction alopecia – caused by prolonged tension on the hair from certain hairstyles

• Scarring alopecias (e.g., lichen planopilaris, folliculitis decalvans) – a group of conditions in which inflammation destroys hair follicles permanently; early dermatology assessment is important to limit irreversible loss

Certain medications are also recognised causes of hair loss, including chemotherapy agents, anticoagulants, some antihypertensives (e.g., beta-blockers), retinoids, valproate, and antithyroid drugs. If you suspect a medication may be contributing to hair loss, discuss this with your prescribing clinician before making any changes. Thyroid disorders and iron deficiency anaemia are systemic conditions that should be excluded, particularly when hair loss is diffuse or accompanied by other symptoms; targeted blood tests (full blood count, ferritin, TSH) are appropriate when clinically indicated.

Red-flag features that warrant prompt GP or dermatology review include: scalp pain, erythema, pustules, or scarring; rapidly progressive or widespread loss; patchy loss with broken hairs or scaling; and hair loss accompanied by systemic symptoms such as fatigue, weight change, or skin changes. Understanding the underlying cause is essential before selecting any treatment, as the most effective approach will differ considerably depending on the diagnosis.

Not sure if this is normal? Chat with one of our pharmacists →

Clinically Evidenced Hair Loss Treatments Available in the UK

Finasteride 1 mg and topical minoxidil are the only two MHRA-licensed medicines for male pattern baldness in the UK; other options such as PRP and LLLT lack strong guideline endorsement.

In the UK, a number of hair loss treatments are available that have been evaluated in clinical trials. It is important to distinguish between treatments that are MHRA-licensed for androgenetic alopecia in men and those that are not.

The only two MHRA-licensed medicines for male pattern hair loss in men are:

• Finasteride 1 mg (oral, prescription-only medicine) – licensed for androgenetic alopecia in adult men

• Topical minoxidil (2% and 5% solution or foam) – available over the counter or on prescription

Both have been shown in randomised controlled trials to slow hair loss and, in many cases, promote regrowth when used consistently.

Other options are available but are not MHRA-licensed medicines for androgenetic alopecia:

• Low-level laser therapy (LLLT) – devices such as laser combs and helmets are regulated as medical devices rather than medicines; some studies have shown modest benefit, but evidence remains limited and no strong guideline endorsement exists

• Platelet-rich plasma (PRP) therapy – an unlicensed procedure involving injections of concentrated growth factors; early evidence is promising but heterogeneous, and it is not currently recommended by NICE or the BAD as a standard treatment

• Hair transplant surgery – techniques such as follicular unit extraction (FUE) and follicular unit transplantation (FUT) offer a long-term solution for suitable candidates, though they are costly and not without risk

• Ketoconazole shampoo – a licensed antifungal useful for seborrhoeic dermatitis of the scalp; evidence for meaningful hair regrowth in androgenetic alopecia is weak, and it should not be considered a treatment for male pattern baldness

It is advisable to approach products claiming dramatic results without clinical backing with caution. The NHS, NICE CKS, and the British Association of Dermatologists (BAD) do not recommend commercially marketed supplements or unproven topical serums as evidence-based treatments for androgenetic alopecia.

Finasteride and Minoxidil: What the Evidence Says

Finasteride halted hair loss in 83–87% of men after two years in clinical trials, while topical minoxidil promotes regrowth particularly at the crown; both require continuous use to maintain benefit.

Finasteride 1 mg works by inhibiting the enzyme 5-alpha reductase, which converts testosterone into DHT. By reducing scalp DHT levels by approximately 60–70%, finasteride slows follicle miniaturisation and can stimulate regrowth in a significant proportion of men. Clinical trial data (referenced in the MHRA-approved Summary of Product Characteristics) indicate that around 83–87% of men taking 1 mg finasteride daily experienced no further hair loss after two years, with approximately two-thirds showing measurable regrowth. It is licensed in the UK for male pattern baldness in adult men and is available on prescription only.

Important safety information for finasteride:

• Psychiatric effects: The MHRA has issued a Drug Safety Update (2024) advising that finasteride is associated with a risk of depression and suicidal thoughts. If you experience low mood, depression, or any thoughts of self-harm or suicide whilst taking finasteride, stop taking it and seek medical help immediately.

• Sexual side effects such as reduced libido, erectile dysfunction, and decreased ejaculate volume have been reported; in some men, these effects have persisted after stopping treatment. Discuss any such symptoms with your prescribing clinician.

• An MHRA patient alert card is provided with finasteride prescriptions; read it carefully before starting treatment.

• Finasteride is contraindicated in women who are or may become pregnant. Pregnant women should not handle crushed or broken tablets due to the risk of absorption and potential harm to a male foetus.

• Results typically take 3–6 months to become apparent, and treatment must be continued to maintain benefit; hair loss generally resumes within 6–12 months of stopping.

Minoxidil was originally developed as an antihypertensive agent; its hair-promoting effects were discovered as a side effect. Applied topically (2% or 5% solution or foam), it is thought to prolong the anagen (growth) phase of the hair cycle and improve follicular blood supply. Evidence supports its efficacy in slowing loss and promoting regrowth, particularly at the crown. An initial increase in shedding during the first 2–4 weeks of use is common and does not indicate treatment failure. Visible benefit is typically seen after 2–4 months of consistent use. Common side effects include scalp irritation and, less commonly, unwanted facial hair growth.

Oral low-dose minoxidil is increasingly used for hair loss but is not licensed for this indication in the UK and is therefore prescribed off-label. It should only be initiated by a clinician following appropriate assessment, including baseline blood pressure measurement and cardiovascular review. Potential side effects include fluid retention, oedema, increased heart rate, and, rarely, pericardial effusion. Men with cardiovascular conditions should discuss this option carefully with their doctor before use.

Suspected side effects from any hair loss medicine should be reported via the MHRA Yellow Card scheme at www.mhra.gov.uk/yellowcard.

Accessing Hair Loss Treatment on the NHS or Privately

NHS treatment for male pattern baldness is not routinely available as it is classified as cosmetic; men can access finasteride and minoxidil privately via a GP, dermatologist, or CQC-registered online prescribing service.

In the UK, access to hair loss treatment through the NHS is limited, primarily because male pattern baldness is classified as a cosmetic condition rather than a medical one. As a result, finasteride for androgenetic alopecia is not routinely prescribed on the NHS, and hair transplant surgery is not funded. However, if hair loss is secondary to an underlying medical condition — such as alopecia areata, thyroid disease, or iron deficiency — investigation and treatment of that condition may be available through your GP. Further information is available on the NHS hair loss page.

For men seeking treatment for androgenetic alopecia, the most common routes are:

• Private GP or dermatologist consultation – a clinician can assess the pattern and severity of hair loss, exclude underlying causes, and prescribe finasteride or oral minoxidil (off-label) where appropriate

• Online prescribing services – several online platforms offer consultations and prescriptions for finasteride and topical minoxidil; it is important to use services registered with the Care Quality Commission (CQC), with prescriptions dispensed by a General Pharmaceutical Council (GPhC)-registered pharmacy, and clinicians who are GMC-registered. You can verify these registrations via the CQC website, the GPhC online register, and the GMC online register respectively.

• Over-the-counter topical minoxidil – 2% and 5% formulations are available without prescription from pharmacies and are a reasonable first step for many men

Patients should be cautious about purchasing prescription medicines from unregulated online sources, as product quality and safety cannot be guaranteed.

When to seek prompt medical advice: Contact your GP if you notice sudden or patchy hair loss, loss associated with scalp inflammation, pain, or scarring, or hair loss accompanied by systemic symptoms such as fatigue or weight change. Early dermatology referral is recommended for suspected scarring alopecia, diagnostic uncertainty, severe or rapidly progressive alopecia areata, or suspected tinea capitis (particularly in children), as these conditions may require specialist assessment and treatment to prevent permanent hair loss.

How to Choose the Right Treatment for Your Hair Loss

For early-to-moderate androgenetic alopecia, a combination of finasteride and topical minoxidil is widely used; choice should be guided by severity, side-effect tolerance, and a professional consultation to confirm diagnosis.

Selecting the most appropriate treatment begins with an honest assessment of the type, pattern, and duration of your hair loss, as well as your personal health history and treatment goals. For the majority of men with early-to-moderate androgenetic alopecia, a combination of finasteride and topical minoxidil is widely used; studies suggest the two treatments may provide additive benefit, as they work via complementary mechanisms, though individual responses vary.

When weighing up your options, consider the following:

• Severity of hair loss – early intervention generally yields better outcomes; treatments are more effective at maintaining existing hair than regrowing hair that has been lost for many years

• Tolerance of side effects – finasteride carries important safety considerations, including risks of depression, suicidal thoughts, and persistent sexual dysfunction (see the section above and the MHRA patient alert card). If you have concerns about these effects, topical minoxidil alone or low-level laser therapy may be preferable starting points; discuss your options with a clinician

• Commitment to long-term use – both finasteride and minoxidil require ongoing use; stopping treatment typically results in resumed hair loss within 6–12 months

• Budget – hair transplant surgery can cost between £3,000 and £15,000 privately in the UK and represents a significant financial commitment

• Underlying health conditions – oral minoxidil is off-label for hair loss and requires clinician assessment, baseline blood pressure measurement, and follow-up before and during use; men with cardiovascular conditions should discuss this carefully with their doctor

• Hair transplant surgery – if considering surgery, choose a provider registered with the CQC and consider whether the surgeon holds membership of the British Association of Hair Restoration Surgery (BAHRS); discuss realistic expectations, donor hair limitations, and potential risks at consultation

It is strongly recommended to seek a professional consultation before starting any prescription treatment. A GP or dermatologist can confirm the diagnosis, rule out reversible causes, and tailor a treatment plan to your individual circumstances. Reputable resources include the NHS hair loss page, the British Association of Dermatologists (BAD) patient information on male pattern hair loss, and NICE Clinical Knowledge Summaries (CKS). Avoid making decisions based solely on marketing claims, and be wary of treatments promising rapid or guaranteed results — no currently available treatment offers a permanent cure for androgenetic alopecia.

If you experience any suspected side effects from a hair loss medicine, report them via the MHRA Yellow Card scheme at www.mhra.gov.uk/yellowcard.

Frequently Asked Questions